Targeting p19 in psoriatic arthritis: more than just another therapeutic approach?

Affiliations

¹ Department of Medicine III, Division of Rheumatology, Medical University of Vienna, 1090 Vienna, Austria. Electronic address: andreas.kerschbaumer@meduniwien.ac.at.
² Department of Medicine III, Division of Rheumatology, Medical University of Vienna, 1090 Vienna, Austria.

Comment

Andreas Kerschbaumer et al. Lancet. 2020.

. 2020 Apr 4;395(10230):1091-1093.

doi: 10.1016/S0140-6736(20)30525-0. Epub 2020 Mar 13.

¹ Department of Medicine III, Division of Rheumatology, Medical University of Vienna, 1090 Vienna, Austria. Electronic address: andreas.kerschbaumer@meduniwien.ac.at.
² Department of Medicine III, Division of Rheumatology, Medical University of Vienna, 1090 Vienna, Austria.

No abstract available

Comment on

Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial.
Deodhar A, Helliwell PS, Boehncke WH, Kollmeier AP, Hsia EC, Subramanian RA, Xu XL, Sheng S, Agarwal P, Zhou B, Zhuang Y, Ritchlin CT; DISCOVER-1 Study Group. Deodhar A, et al. Lancet. 2020 Apr 4;395(10230):1115-1125. doi: 10.1016/S0140-6736(20)30265-8. Epub 2020 Mar 13. Lancet. 2020. PMID: 32178765 Clinical Trial.
Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial.
Mease PJ, Rahman P, Gottlieb AB, Kollmeier AP, Hsia EC, Xu XL, Sheng S, Agarwal P, Zhou B, Zhuang Y, van der Heijde D, McInnes IB; DISCOVER-2 Study Group. Mease PJ, et al. Lancet. 2020 Apr 4;395(10230):1126-1136. doi: 10.1016/S0140-6736(20)30263-4. Epub 2020 Mar 13. Lancet. 2020. PMID: 32178766 Clinical Trial.